In vivo effects of the pure aryl hydrocarbon receptor antagonist GNF-351 after oral administration are limited to the gastrointestinal tract

British Journal of Pharmacology

Volumn 171, Issue 7, 2014, Pages 1735-1746

  Fang, Zhong Ze ^a   Krausz, Kristopher W ^a   Nagaoka, Kenjiro ^a   Tanaka, Naoki ^a   Gowda, Krishne ^b   Amin, Shantu G ^b   Perdew, Gary H ^c   Gonzalez, Frank J ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b PENN STATE COLLEGE OF MEDICINE   (United States)

^c PENNSYLVANIA STATE UNIVERSITY   (United States)

Author keywords

absorption; AHR antagonist; GNF 351; metabolic map

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CYTOCHROME P450 1A1; CYTOCHROME P450 1A2; CYTOCHROME P450 3A4; GNF 351; MESSENGER RNA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CONCENTRATION RESPONSE; DEMETHYLATION; DRUG ABSORPTION; DRUG EFFICACY; DRUG METABOLISM; DRUG STRUCTURE; DUODENUM; ENZYME ACTIVITY; GASTROINTESTINAL TRACT; GLUCURONIDATION; HUMAN; HUMAN CELL; IN VIVO STUDY; JEJUNUM; MALE; METABOLOMICS; MICROSOME; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTON TRANSPORT;

ABSORPTION; AHR ANTAGONIST; GNF-351; METABOLIC MAP;

ADMINISTRATION, ORAL; ANIMALS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; FECES; GENE EXPRESSION REGULATION; HUMANS; INDOLES; INTESTINAL ABSORPTION; INTESTINES; MALE; METABOLOMICS; MICE; MICE, INBRED C57BL; MICROSOMES, LIVER; PURINES; RECEPTORS, ARYL HYDROCARBON; SPECTROMETRY, MASS, ELECTROSPRAY IONIZATION; SPECTROMETRY, MASS, MATRIX-ASSISTED LASER DESORPTION-IONIZATION;

EID: 84905041987     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/bph.12576     Document Type: Article

References (22)

1. Alexander SPH, Benson HE, Faccenda E, Pawson AJ, Sharman JL, Spedding M, et al. (2013). The Concise Guide to PHARMACOLOGY 2013/14: Nuclear Hormone Receptors. Br J Pharmacol 170, 1652-1675.
2. Barouki R, Coumoul X, Fernandez-Salguero PM, (2007). The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett 581: 3608-3615.
3. Fang ZZ, Krausz KW, Li F, Cheng J, Tanaka N, Gonzalez FJ, (2012). Metabolic map and bioactivation of the anti-tumour drug noscapine. Br J Pharmacol 167: 1271-1286.
4. Fernandez-Salguero P, Pineau T, Hilbert DM, McPhail T, Lee SS, Kimura S, et al. (1995). Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 268: 722-726.
5. Fuchs I, Hafner-Blumenstiel V, Markert C, Burhenne J, Weiss J, Haefeli WE, et al. (2013). Effect of the CYP3A inhibitor ketoconazole on the PXR-mediated induction of CYP3A activity. Eur J Clin Pharmacol 69: 507-513.
6. Granvil CP, Yu AM, Elizondo G, Akiyama TE, Cheung C, Feigenbaum L, et al. (2003). Expression of the human CYP3A4 gene in the small intestine of transgenic mice: in vitro metabolism and pharmacokinetics of midazolam. Drug Metab Dispos 31: 548-558.
7. Johnson CH, Gonzalez FJ, (2012). Challenges and opportunities of metabolomics. J Cell Physiol 227: 2975-2981.
8. Johnson CH, Patterson AD, Idle JR, Gonzalez FJ, (2012). Xenobiotic metabolomics: major impact on the metabolome. Annu Rev Pharmacol Toxicol 52: 37-56.
9. Kaivosaari S, Finel M, Koskinen M, (2011). N-glucuronidation of drugs and other xenobiotics by human and animal UDP-glucuronosyltransferases. Xenobiotica 41: 652-669.
10. Kilkenny C, Browne W, Cuthill IC, Emerson M, Altman DG, (2010). Animal research: reporting in vivo experiments: the ARRIVE guidelines. Br J Pharmacol 160: 1577-1579.
11. Kim SH, Henry EC, Kim DK, Kim YH, Shin KJ, Han MS, et al. (2006). Novel compound 2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazo-phenyl)-amide (CH-223191) prevents 2,3,7,8-TCDD-induced toxicity by antagonizing the aryl hydrocarbon receptor. Mol Pharmacol 69: 1871-1878.
12. Kohle C, Bock KW, (2007). Coordinate regulation of Phase I and II xenobiotic metabolisms by the Ah receptor and Nrf2. Biochem Pharmacol 73: 1853-1862.
13. Li F, Lu J, Cheng J, Wang L, Matsubara T, Csanaky IL, et al. (2013). Human PXR modulates hepatotoxicity associated with rifampicin and isoniazid co-therapy. Nat Med 19: 418-420.
14. Ma X, Shah YM, Guo GL, Wang T, Krausz KW, Idle JR, et al. (2007). Rifaximin is a gut-specific human pregnane X receptor activator. J Pharmacol Exp Ther 322: 391-398.
15. Matsubara T, Tanaka N, Krausz KW, Manna SK, Kang DW, Anderson ER, et al. (2012). Metabolomics identifies an inflammatory cascade involved in dioxin- and diet-induced steatohepatitis. Cell Metab 16: 634-644.
16. McGrath J, Drummond G, McLachlan E, Kilkenny C, Wainwright C, (2010). Guidelines for reporting experiments involving animals: the ARRIVE guidelines. Br J Pharmacol 160: 1573-1576.
17. Pellegatti M, (2012). Preclinical in vivo ADME studies in drug development: a critical review. Expert Opin Drug Metab Toxicol 8: 161-172.
18. Rais R, Acharya C, Mackerell AD, Polli JE, (2010). Structural determinants for transport across the intestinal bile acid transporter using C-24 bile acid conjugates. Mol Pharm 7: 2240-2254.
19. Scandlyn MJ, Stuart EC, Rosengren RJ, (2008). Sex-specific differences in CYP450 isoforms in human. Expert Opin Drug Metab Toxicol 4: 413-424.
20. Smith KJ, Murray IA, Tanos R, Tellew J, Boitano AE, Bisson WH, et al. (2011). Identification of a high-affinity ligand that exhibits complete aryl hydrocarbon receptor antagonism. J Pharmacol Exp Ther 338: 318-327.
21. Veldhoen M, Hirota K, Christensen J, O'Garra A, Stockinger B, (2009). Natural agonists for aryl hydrocarbon receptor in culture medium are essential for optimal differentiation of Th17 T cells. J Exp Med 206: 43-49.
22. Vondracek J, Umannova L, Machala M, (2011). Interactions of the aryl hydrocarbon receptor with inflammatory mediators: beyond CYP1A regulation. Curr Drug Metab 12: 89-103.